Encysive Holds Hope For Thelin Despite Receiving Second “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says it does not anticipate having to collect additional data on the pulmonary arterial hypertension drug.
You may also be interested in...
Encysive Thelin Approval Could Come Days Ahead Of Gilead’s Ambrisentan
FDA’s regulatory timeline for reviewing the two pulmonary arterial hypertension medications may fall neck and neck.
Encysive Thelin Approval Could Come Days Ahead Of Gilead’s Ambrisentan
FDA’s regulatory timeline for reviewing the two pulmonary arterial hypertension medications may fall neck and neck.
Encysive Hits Another Snag With Thelin
FDA requests the company reformat information included in its response to a second “approvable” letter.